Infliximab De-escalation in Patients With Crohn's Disease in Clinical Remission Is Safe and Well-tolerated
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Inflammatory bowel diseases - 27(2021), 12 vom: 15. Nov., Seite 2031-2033 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Allegretti, Jessica R [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Monoclonal |
|---|
| Anmerkungen: |
Date Completed 10.02.2022 Date Revised 10.02.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/ibd/izab131 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM326902244 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM326902244 | ||
| 003 | DE-627 | ||
| 005 | 20231225195608.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ibd/izab131 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1089.xml |
| 035 | |a (DE-627)NLM326902244 | ||
| 035 | |a (NLM)34142700 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Allegretti, Jessica R |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Infliximab De-escalation in Patients With Crohn's Disease in Clinical Remission Is Safe and Well-tolerated |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.02.2022 | ||
| 500 | |a Date Revised 10.02.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Crohn’s disease | |
| 650 | 4 | |a dose de-escalation | |
| 650 | 4 | |a inflammatory bowel disease | |
| 650 | 4 | |a infliximab | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Gastrointestinal Agents |2 NLM | |
| 650 | 7 | |a Infliximab |2 NLM | |
| 650 | 7 | |a B72HH48FLU |2 NLM | |
| 700 | 1 | |a Canakis, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a McClure, Emma |e verfasserin |4 aut | |
| 700 | 1 | |a Marcus, Jenna |e verfasserin |4 aut | |
| 700 | 1 | |a Norton, Beth-Ann |e verfasserin |4 aut | |
| 700 | 1 | |a Hamilton, Matthew J |e verfasserin |4 aut | |
| 700 | 1 | |a Winter, Rachel W |e verfasserin |4 aut | |
| 700 | 1 | |a De Silva, Punyanganie S |e verfasserin |4 aut | |
| 700 | 1 | |a Friedman, Sonia |e verfasserin |4 aut | |
| 700 | 1 | |a Korzenik, Joshua R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Inflammatory bowel diseases |d 1995 |g 27(2021), 12 vom: 15. Nov., Seite 2031-2033 |w (DE-627)NLM094498598 |x 1536-4844 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2021 |g number:12 |g day:15 |g month:11 |g pages:2031-2033 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/ibd/izab131 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2021 |e 12 |b 15 |c 11 |h 2031-2033 | ||